CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Bacac, Marina ^a   Klein, Christian ^a   Umana, Pablo ^a  

^a Roche Innovation Center Zurich   (Switzerland)

Author keywords

Bispecific; T cell

Indexed keywords

BISPECIFIC ANTIBODY; BLINATUMOMAB; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84981517870     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1203498     Document Type: Article

References (10)

1. S.R.Frankel, P.A.Baeuerle. Targeting t cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17(3):385-92; PMID:23623807; http://dx.doi.org/10.1016/j.cbpa.2013.03.029
2. R.Bargou, E.Leo, G.Zugmaier, M.Klinger, M.Goebeler, S.Knop, R.Noppeney, A.Viardot, G.Hess, M.Schuler et al. Tumor regression in cancer patients by very low doses of a t cell-engaging antibody. Science 2008; 321(5891):974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545
3. D.Przepiorka, C.W.Ko, A.Deisseroth, C.L.Yancey, R.Candau-Chacon, H.J.Chiu, B.J.Gehrke, C.Gomez-Broughton, R.C.Kane, S.Kirshner et al. Fda approval:Blinatumomab. Clin Cancer Res 2015; 21(18):4035-9; PMID:26374073; http://dx.doi.org/10.1158/1078-0432.CCR-15-0612
4. L.L.Sun, D.Ellerman, M.Mathieu, M.Hristopoulos, X.Chen, Y.Li, X.Yan, R.Clark, A.Reyes, E.Stefanich et al. Anti-cd20/cd3 t cell-dependent bispecific antibody for the treatment of b cell malignancies. Sci Transl Med 2015; 7(287):287ra270; PMID:25972002; http://dx.doi.org/10.1126/scitranslmed.aaa4802
5. E.J.Smith, K.Olson, L.J.Haber, B.Varghese, P.Duramad, A.D.Tustian, A.Oyejide, J.R.Kirshner, L.Canova, J.Menon et al. A novel, native-format bispecific antibody triggering t-cell killing of b-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 2015; 5:17943; PMID:26659273; http://dx.doi.org/10.1038/srep17943
6. M.Bacac, T.Fauti, J.Sam, S.Colombetti, T.Weinzierl, D.Ouaret, W.F.Bodmer, S.Lehmann, T.Hofer, R.J.Hosse et al. A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors. Clin Cancer Res 2016 Jul 1; 22(13):3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696
7. L.Peng, M.D.Oberst, J.Huang, P.Brohawn, C.Morehouse, K.Lekstrom, P.A.Baeuerle, H.Wu, Y.Yao, S.R.Coats et al. The cea/cd3-bispecific antibody medi-565 (mt111) binds a nonlinear epitope in the full-length but not a short splice variant of cea. PLoS One 2012; 7(5):e36412; PMID:22574157; http://dx.doi.org/10.1371/journal.pone.0036412
8. S.Lehmann, R.Perera, H.P.Grimm, J.Sam, S.Colombetti, T.Fauti, L.Fahrni, T.Schaller, A.Freimoser-Grundschober, J.Zielonka et al. In vivo imaging of the activity of cea tcb, a novel t-cell bispecific antibody, reveals specific tumor targeting and fast induction of t-cell mediated tumor killing. Clin Cancer Res 2016 Apr 26; pii:clincanres.2622.2015. [Epub ahead of print]; PMID:27117182; http://dx.doi.org/10.1158/1078-0432.CCR-15-2622
9. T.Dao, D.Pankov, A.Scott, T.Korontsvit, V.Zakhaleva, Y.Xu, J.Xiang, S.Yan, M.D.de Morais Guerreiro, N.Veomett et al. Therapeutic bispecific t-cell engager antibody targeting the intracellular oncoprotein wt1. Nat Biotechnol 2015; 33(10):1079-86; PMID:26389576; http://dx.doi.org/10.1038/nbt.3349
10. S.Dudal, H.Hinton, A.M.Giusti, M.Bacac, M.Muller, T.Fauti, S.Colombetti, T.Heckel, N.Giroud, C.Klein et al. Application of a mabel approach for a t cell bispecific monoclonal antibody:Cea tcb. J Immunother 2016 Jul 11; [Epub ahead of print]; PMID:27404941; http://dx.doi.org/10.1097/CJI.0000000000000132